Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 993,800 shares, an increase of 158.2% from the September 15th total of 384,900 shares. Based on an average daily volume of 2,430,000 shares, the short-interest ratio is currently 0.4 days. Currently, 1.2% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

UNCY has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $2.50 target price on shares of Unicycive Therapeutics in a report on Wednesday. Brookline Capital Management raised Unicycive Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 9th. Finally, Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $5.13.

Hedge Funds Weigh In On Unicycive Therapeutics

An institutional investor recently bought a new position in Unicycive Therapeutics stock. Virtu Financial LLC acquired a new position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 26,082 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned 0.07% of Unicycive Therapeutics at the end of the most recent quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Stock Up 3.1 %

UNCY stock traded up $0.01 during trading hours on Friday, hitting $0.37. The company’s stock had a trading volume of 1,159,113 shares, compared to its average volume of 1,496,478. The company has a market capitalization of $34.91 million, a PE ratio of -0.35 and a beta of 2.36. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The stock has a 50 day moving average price of $0.37 and a two-hundred day moving average price of $0.68.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08. Sell-side analysts expect that Unicycive Therapeutics will post -0.26 earnings per share for the current year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.